Exclusive Summary

• Backed by dual US-FDA and EU-EMA GMP certifications with active registration in Germany, instantly eliminating quality-trust barriers and accelerating global market entry.
• Offers dual strengths (2mg/ml and 10mg/ml) to comprehensively address clinical needs raging from standard post-operative pain to severe cancer pain in opioid-tolerant patients.
• Directly targets frequent supply chain shortages of controlled sterile injectables in the US, EU, and other markets by serving as a highly reliable, premium alternative manufacturer.
• Stands as a rigid-demand, core Step-3 drug in the WHO analgesic ladder and NCCN guidelines, catering to an enormous global patient population suffering from moderate-to-severe pain.
• Leverages China's cost-efficient manufacturing ecosystem to provide overseas distributors with highly competitive COGS, ensuring robust profit margins in local tenders and procurement.